BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...engineering NK cell receptors into T cells to make the T cells act more NK-like. Courier Therapeutics Inc....
...NKp30; NCR3; CD337) Preclin Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) CYAD-101 Allogenic CAR T cells NKG2D Preclin Courier Therapeutics Inc....
...Euronext:IPH) IPH4301 Antibody MICA / MICB Preclin Four companies -- Oxford, Innate, CanCure LLC and Courier Therapeutics Inc....
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...Celyad has found no evidence in vitro that MICA and MICB down-regulate the chimeric receptor. Courier Therapeutics Inc....
...and Development (CDRD), Vancouver, B.C. CanCure LLC, Everett, Wash. Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Courier Therapeutics Inc....
...Advance (2017) Mark Zipkin, Staff Writer American Association for Cancer Research CanCure LLC Celyad S.A. Centre for Drug Research and Development Courier Therapeutics Inc. Innate...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...strategy that not only avoids the adverse events but boosts efficacy, and has spun out Courier Therapeutics Inc....
...from Bristol-Myers Squibb Co. (NYSE:BMY) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528), in 821 patients. Source: Courier Therapeutics Inc....
...IL-2 are in clinical development, and three others are in preclinical development, including CT101-IL2 from Courier Therapeutics Inc....
Items per page:
1 - 3 of 3
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...engineering NK cell receptors into T cells to make the T cells act more NK-like. Courier Therapeutics Inc....
...NKp30; NCR3; CD337) Preclin Celyad S.A. (NASDAQ:CYAD; Euronext:CYAD) CYAD-101 Allogenic CAR T cells NKG2D Preclin Courier Therapeutics Inc....
...Euronext:IPH) IPH4301 Antibody MICA / MICB Preclin Four companies -- Oxford, Innate, CanCure LLC and Courier Therapeutics Inc....
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...Celyad has found no evidence in vitro that MICA and MICB down-regulate the chimeric receptor. Courier Therapeutics Inc....
...and Development (CDRD), Vancouver, B.C. CanCure LLC, Everett, Wash. Celyad S.A. (Euronext:CYAD; NASDAQ:CYAD), Mont-Saint-Guibert, Belgium Courier Therapeutics Inc....
...Advance (2017) Mark Zipkin, Staff Writer American Association for Cancer Research CanCure LLC Celyad S.A. Centre for Drug Research and Development Courier Therapeutics Inc. Innate...
BioCentury | Oct 27, 2016
Targets & Mechanisms

Cancer’s Phoenix

...strategy that not only avoids the adverse events but boosts efficacy, and has spun out Courier Therapeutics Inc....
...from Bristol-Myers Squibb Co. (NYSE:BMY) and Ono Pharmaceutical Co. Ltd. (Tokyo:4528), in 821 patients. Source: Courier Therapeutics Inc....
...IL-2 are in clinical development, and three others are in preclinical development, including CT101-IL2 from Courier Therapeutics Inc....
Items per page:
1 - 3 of 3